SecBot SecBot
8-K ·Filed Jul 20, 2026

RGNX

REGENXBIO Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001193125-26-308342
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The dilutive offering will increase share count by ~22% (excluding warrants), likely pressuring RGNX shares near-term as the market absorbs supply. Monitor for use of proceeds toward pipeline programs (RGX-202, ABBV-RGX-314, NAVSUNLI) and any clinical updates that could offset dilution sentiment.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

RGNX drug pipeline →

surabgene lomparvovec

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
Next catalyst
None dated

What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.32
T+0 close · Jul 20, 2026 · via day close
Latest settled
−29.65%
T+60 · $7.26
Vs SPY
−34.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $10.32entry
  2. T+1 · 4mo ago +0.19%α −0.64% · $10.34
  3. T+5 · 4mo ago −5.72%α −5.29% · $9.73
  4. T+20 · 3mo ago +9.79%α +5.67% · $11.33
  5. T+60 · 5w ago −29.65%α −34.49% · $7.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. Underwriters fully exercised their option for an additional 1,667,250 shares. Net proceeds are expected to be approximately $107.8 million. The offering closes July 20, 2026.

Key Facts

  • Priced 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
  • Underwriters exercised option in full for 1,667,250 additional shares
  • Net proceeds expected to be approximately $107.8 million
  • Pre-funded warrants have $0.0001 exercise price, exercisable at any time with no expiration
  • Offering expected to close July 20, 2026

Financial Impact

Dilution of approximately 22% from new shares alone, plus potential dilution from 1,111,111 warrant shares; net proceeds of ~$107.8M added to cash position

dilutioncash

Risk Factors

  • Significant dilution to existing shareholders
  • Potential overhang from pre-funded warrants exercisable at $0.0001
  • Clinical-stage biotech with no approved products; capital needs may require further offerings

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-308342
Document: d40931dex41.htm0001193125-26-308342
Document: d40931d8k.htm0001193125-26-308342
Document: d40931dex51.htm0001193125-26-308342
Document: d40931dex991.htm0001193125-26-308342
Document: 0001193125-26-308342-index-headers.html0001193125-26-308342
Document: 0001193125-26-308342-index.html0001193125-26-308342
Document: 0001193125-26-308342.txt0001193125-26-308342

Track record

15 reports on RGNX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.36% at T+5 after the Jun 29, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Viewing Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026